The market isn't taking the U.S. Federal Reserve's rumination on stock prices too seriously. Twitter and Amgen extended rallies in social media and biotechnology stocks since the U.S. central bank said two weeks ago that industry valuations are stretched. The microblogging service rose 20 percent as second-quarter revenue topped analyst estimates.